Russia plans to speed registration of Trikafta

9 July 2022

Russia plans to speed registration of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), an expensive drug from the USA’s Vertex Pharmaceuticals (Nasdaq: VRTX), which is indicated for the treatment of cystic fibrosis.

So far, representatives of patient community have already called on the Russian Ministry of Health to speed registration of the drug.

According to them, procurements of the drug should be carried out as part 14 VZN federal program (which regulates procurements of the most expensive drug for state needs).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK